NO20091741L - Pyrazolinforbindelser som mineralkortikoidreceptorantagonister - Google Patents
Pyrazolinforbindelser som mineralkortikoidreceptorantagonisterInfo
- Publication number
- NO20091741L NO20091741L NO20091741A NO20091741A NO20091741L NO 20091741 L NO20091741 L NO 20091741L NO 20091741 A NO20091741 A NO 20091741A NO 20091741 A NO20091741 A NO 20091741A NO 20091741 L NO20091741 L NO 20091741L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- pyrazoline compounds
- mineral corticoid
- corticoid receptor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Forbindelser og farmasøytisk akseptable salter av forbindelsene er beskrevet, hvori forbindelsene har strukturen med Formel I: Hvori RI, R2, R3a, R3B, R4, R5, R6, R7, R8 og X er som definert i den detaljerte beskrivelsen av oppfinnelsen. Korresponderende farmasøytiske sammensetninger, fremgangsmåter for behandling og intermediater er også beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86360606P | 2006-10-31 | 2006-10-31 | |
PCT/IB2007/003207 WO2008053300A1 (en) | 2006-10-31 | 2007-10-17 | Pyrazoline compounds as mineralocorticoid receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091741L true NO20091741L (no) | 2009-05-29 |
Family
ID=39027523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091741A NO20091741L (no) | 2006-10-31 | 2009-05-04 | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister |
Country Status (40)
Country | Link |
---|---|
US (3) | US7781428B2 (no) |
EP (1) | EP2089367B1 (no) |
JP (1) | JP4977760B2 (no) |
KR (1) | KR101107800B1 (no) |
CN (1) | CN101541757A (no) |
AP (1) | AP2527A (no) |
AR (1) | AR063529A1 (no) |
AT (1) | ATE537151T1 (no) |
AU (1) | AU2007315884B2 (no) |
BR (1) | BRPI0717937A2 (no) |
CA (1) | CA2667966C (no) |
CL (1) | CL2007003154A1 (no) |
CO (1) | CO6160307A2 (no) |
CR (1) | CR10725A (no) |
CU (1) | CU23779B7 (no) |
CY (1) | CY1112311T1 (no) |
DK (1) | DK2089367T3 (no) |
EA (1) | EA016370B1 (no) |
ES (1) | ES2375877T3 (no) |
GE (1) | GEP20115239B (no) |
GT (1) | GT200700096A (no) |
HN (1) | HN2007000437A (no) |
HR (1) | HRP20120078T1 (no) |
IL (1) | IL198241A0 (no) |
MA (1) | MA30821B1 (no) |
MX (1) | MX2009004662A (no) |
MY (1) | MY145795A (no) |
NI (1) | NI200900071A (no) |
NO (1) | NO20091741L (no) |
NZ (1) | NZ575923A (no) |
PE (1) | PE20081472A1 (no) |
PL (1) | PL2089367T3 (no) |
PT (1) | PT2089367E (no) |
RS (2) | RS52203B (no) |
SI (1) | SI2089367T1 (no) |
TN (1) | TN2009000160A1 (no) |
TW (1) | TWI357327B (no) |
UA (1) | UA92670C2 (no) |
UY (1) | UY30670A1 (no) |
WO (1) | WO2008053300A1 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
WO2011059784A1 (en) * | 2009-10-29 | 2011-05-19 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
ES2566934T3 (es) | 2010-05-10 | 2016-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina |
CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
CN102372710A (zh) * | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
US10172907B2 (en) | 2010-10-05 | 2019-01-08 | Nova Southeastern University | Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease |
RS58274B1 (sr) | 2014-06-30 | 2019-03-29 | Astrazeneca Ab | Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora |
JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
US20190262363A1 (en) | 2016-07-26 | 2019-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
WO2018045149A1 (en) | 2016-09-02 | 2018-03-08 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
CN109051490A (zh) | 2018-09-18 | 2018-12-21 | 深圳市鲸仓科技有限公司 | 可移动式密集存拣装置 |
EP4118235A1 (en) | 2020-03-11 | 2023-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1086068A (en) * | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
BE789948A (fr) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
US3816438A (en) * | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US4866025A (en) * | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
ES2098547T3 (es) * | 1992-01-23 | 1997-05-01 | Pfizer | Benzopirano y otros antagonistas de ltb4 relacionados. |
GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
JP2001501180A (ja) * | 1996-09-05 | 2001-01-30 | アストラ・フアーマシユウテイカルズ・リミテツド | 新規なアリールピリダジン |
JPH10273467A (ja) * | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
WO1999055335A1 (en) | 1998-04-30 | 1999-11-04 | Basf Aktiengesellschaft | Substituted tricyclic pyrazole derivatives with protein kinase activity |
US6432974B1 (en) * | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
AU2003249597B2 (en) | 2002-03-08 | 2007-06-28 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
WO2003078394A1 (en) | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
BR0313176A (pt) | 2002-08-02 | 2005-06-14 | Vertex Pharma | Composições de pirazol úteis como inibidores de gsk-3 |
CN1681501A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的吡唑衍生物 |
EP1597254A1 (en) | 2003-01-22 | 2005-11-23 | Eli Lilly and Company | Indole-derivative modulators of steroid hormone nuclear receptors |
DE602004014640D1 (de) * | 2003-12-19 | 2008-08-07 | Lilly Co Eli | Tricyclische modulatoren von nuklearen steroidhormonrezeptoren |
JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
WO2006012642A2 (en) | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
CA2593156C (en) | 2005-01-10 | 2015-05-05 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
JPWO2006077821A1 (ja) | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
WO2006086358A2 (en) | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
-
2007
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active IP Right Cessation
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en active Application Filing
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 RS RS20120051A patent/RS52203B/en unknown
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
-
2009
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091741L (no) | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister | |
NO20084129L (no) | Pyridin(3,4-B)Pyrazinoner | |
IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
DE602006017694D1 (de) | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden | |
MY146924A (en) | Substituted imidazoheterocycles | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
TW200745056A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
MX2010006230A (es) | Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3. | |
ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
ATE520651T1 (de) | Substituierte phenylmethylbicyclocarbonsäureamidverbindungen | |
NO20090779L (no) | 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
MX2009004314A (es) | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. | |
NO20091052L (no) | Diaryleterderivater og anvendelser derav | |
MX2013006768A (es) | Moduladores de receptor de glucagon. | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
MY149973A (en) | 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists | |
ATE447575T1 (de) | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren | |
IN2012DN02555A (no) | ||
MX2009000762A (es) | 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central. | |
MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
MX2012003656A (es) | Profarmacos de un derivado de piperidinilo como moduladores de la actividad del receptor de quimiocina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |